Solvonis Therapeutics (LON:SVNS – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported GBX (0.02) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
Solvonis Therapeutics Stock Down 13.0%
LON:SVNS opened at GBX 0.10 on Thursday. The business’s 50-day moving average price is GBX 0.13 and its two-hundred day moving average price is GBX 0.19. Solvonis Therapeutics has a twelve month low of GBX 0.10 and a twelve month high of GBX 0.40. The stock has a market cap of £7.90 million and a P/E ratio of -0.83.
About Solvonis Therapeutics
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers.
The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics.
Featured Articles
- Five stocks we like better than Solvonis Therapeutics
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
Receive News & Ratings for Solvonis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solvonis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
